Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10161895 | 0.82 | EGLN1 (0.43) | EGLN1KDM4EL3MBTL1HRH3TSHR | |
| SCHEMBL30175338 | 0.82 | EGLN1 (0.43) | EGLN1KDM4EL3MBTL1HRH3TSHR | |
| SCHEMBL10161876 | 0.81 | EGLN1 (0.38) | EGLN1KDM4EL3MBTL1HRH3CYP1A2 | |
| SCHEMBL21745145 | 0.81 | EGLN1 (0.39) | EGLN1KDM4EL3MBTL1HRH3CYP1A2 | |
| SCHEMBL10161808 | 0.81 | EGLN1 (0.39) | EGLN1KDM4EL3MBTL1HRH3CYP1A2 | |
| SCHEMBL13514061 | 0.81 | EGLN1 (0.39) | EGLN1KDM4EL3MBTL1HRH3CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL22041901 | 0.79 | EGLN1 (0.39) | EGLN1KDM4EL3MBTL1HRH3CYP1A2 | |
| Hydrochloric Acid SCHEMBL28716738 | 0.78 | EGLN1 (0.38) | EGLN1KDM4EL3MBTL1HRH3CYP1A2 | |
| SCHEMBL23612174 | 0.78 | KMT2A (0.43) | PRKCIKDM4ETSHRHSD17B10MAPK1 | |
| SCHEMBL10160925 | 0.77 | EGLN1 (0.49) | EGLN1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022731-A1 | 2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022731-A1 | 2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS | RET, MECP2, RB1 | EGLN1 1871/4885PRKCI 435/4885KDM4E 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.